✦ LIBER ✦

The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer

✍ Scribed by Linrun Wang; Xiuhua Wu; Mingzhu Huang; Jie Cai; Nong Xu; Jian Liu

Publisher: Springer
Year: 2006
Tongue: English
Weight: 234 KB
Volume: 60
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-006-0363-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of efficacy and toxicity betw

Comparison of efficacy and toxicity between gemcitabine plus cisplatin and plus carboplatin in first-line treatment of advanced non-small cell lung cancer

✍ Meiqi Shi; Bo Shen; Guochun Cao; Yun Zeng; Guohao Xia; Jifeng Feng; Lin Xu 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 80 KB

Fixed-dose rate infusion of gemcitabine

Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer

✍ Gyeong-Won Lee; Myung-Hee Kang; Hoon-Gu Kim; Jung Hun Kang; Seok Hyun Kim; Yu Ji 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 263 KB

Dose escalation study of carboplatin wit

Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma: A study of the lung cancer study group of west Japan

✍ Nobuyuki Katakami; Minoru Takada; Shunichi Negoro; Katsuyasu Ota; Jiro Fujita; K 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 738 KB

## BACKGROUND. We performed a Phase 1-11 trial to determine the maximum tolerated dose of carboplatin (CBDCA) with a fixed dose of VP-16 and granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC) patients. ## METHODS. Treatment consisted of a starting dose of CBDCA, 400